Georgia's Online Cancer Information Center

Find A Clinical Trial

A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

Status
Active
Cancer Type
Acute Lymphoblastic Leukemia
Acute Myelogenous Leukemia
Leukemia
Lymphoma
Neuroblastoma
Trial Phase
Phase I
Eligibility
0 - 25 Years, Male and Female
Study Type
Treatment
NCD ID
NCT03236857
Protocol IDs
M13-833 (primary)
NCI-2017-02027
2017-000439-14
Study Sponsor
Abbvie

Summary

An open-label, global, multi-center study to evaluate the safety and pharmacokinetics of venetoclax monotherapy, to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary efficacy of venetoclax in pediatric and young adult participants with relapsed or refractory malignancies.
Georgia CORE

 

Hearts and Minds Dedicated to Improving Cancer Care

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.